BioSpace News Archive

Continued research and development is critical to advancing care for people with rare diseases who have a significant need for earlier diagnosis, better disease management opportunities, and new treatment options. Sanofi Genzyme, the specialty care global business unit of Sanofi, has been a pioneer in rare diseases with a focus on lysosomal diseases, a group of extremely rare genetic diseases, for more than three decades.

Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement.

NZ Technologies Inc. (NZTech) is pleased to announce the sale of two TIPSO Touchless Image Navigation systems to The Hospital for Sick Children (SickKids) in Toronto, Ontario.

Nancy J. Lavelle, Ph.D., Founder, President and CEO of Total Education Solutions, Inc. (TES), is pleased to announce the acquisition of her Company, effective December 31, 2018

Oxford Gene Technology (OGT), The Molecular Genetics Company, has been granted de novo classification by the US Food and Drug Administration (FDA) for eight Cytocell Aquarius® Haematology fluorescence in situ hybridisation (FISH) probes for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS)

Academia, business professionals, innovators, investors and leading global organizations rely on OFC’s exclusive technical programming

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 29, 2018.

First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced it has closed an oversubscribed $8.25 million Series A-2 financing.

TrialAssure Registry is a premiere clinical trial registration and disclosure reporting application with a configurable workflow engine that allows clients to augment regulatory intelligence for over 30 registries, including ClinicalTrials.gov and EudraCT

Since NGS introduces a relevant number of false positives and false negatives, CENTOGENE has determined how to optimize the use of orthogonal Sanger sequencing of variants in parallel when looking at borderline cases.